Related Experiment Video
Updated: Aug 15, 2026
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
Antiproliferative effect of YM881 (SMANCS) on glioma cells in vitro
1Department of Neurosurgery, Kumamoto University Medical School, Japan.
Abstract:
Growth inhibitory activity of YM881 (SMANCS) against 3 human cultured cell lines and one rat cultured cell line derived from glioma cells was assessed quantitatively. YM881 showed potent cytotoxicity against all glioma cell lines tested; the IC50 of this drug was 1.9-8.4 micrograms/ml. YM881 may be classified as a concentration-dependent drug but it has also a time-dependent effect. Flow cytometric studies of the DNA histogram showed accumulation in the G2-M phase with YM881. These findings suggest that YM881 may be useful in the treatment of glioma.
Insights
YM881 demonstrated potent cytotoxicity against cultured glioma cells, acting in a concentration- and time-dependent manner. This drug may be a promising therapeutic agent for glioma treatment.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Glioma is a primary brain tumor with limited treatment options.
- Developing novel therapeutic agents for glioma is crucial.
Purpose of the Study:
- To evaluate the in vitro growth inhibitory activity of YM881 (SMANCS) against human and rat glioma cell lines.
- To investigate the mechanism of action of YM881 in glioma cells.
Main Methods:
- Quantitative assessment of growth inhibition using cultured glioma cell lines.
- Determination of half maximal inhibitory concentration (IC50).
- Flow cytometry analysis of DNA histograms to assess cell cycle effects.
Main Results:
- YM881 exhibited potent cytotoxicity against all tested glioma cell lines with IC50 values ranging from 1.9-8.4 µg/ml.
- The drug demonstrated both concentration-dependent and time-dependent effects.
- Flow cytometry revealed YM881 induces accumulation of cells in the G2-M phase of the cell cycle.
Conclusions:
- YM881 displays significant anti-glioma activity in vitro.
- The cell cycle arrest at G2-M phase suggests a potential mechanism of action.
- YM881 warrants further investigation as a potential treatment for glioma.
